Clinical Trial Update: AD17002 Treating Poorly Controlled, Moderate to Severe Eosinophilic Asthma [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial AD17002 for poorly controlled, moderate-to-severe eosinophilic asthma has completed Phase 1 and Phase 2 studies.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Eosinophilic Asthma

Drugs mentioned

• AD17002

Snippet

Sponsor: Advagene Biopharma Co. Ltd. | Conditions: Eosinophilic Asthma | Phase 1, Phase 2 | Status: COMPLETED